Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical problems with oral anticoagulation -- 3 case reports].

B Lämmle1

  • 1Hämatologisches Zentrallabor der Universität, Inselspital, Bern. Bernhard.Laemmle@insel.ch

Therapeutische Umschau. Revue Therapeutique
|March 18, 2003
PubMed
Summary

Drug interactions and genetic factors can cause dangerous bleeding in patients taking oral anticoagulants. Doctors should monitor medications and screen for genetic predispositions to ensure patient safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients.

Thrombosis research·2020
Same author

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Association between thyroid dysfunction and venous thromboembolism in the elderly: a prospective cohort study.

Journal of thrombosis and haemostasis : JTH·2016
Same author

High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies.

Journal of thrombosis and haemostasis : JTH·2014
Same author

In vitro rescue of FGA deletion by lentiviral transduction of an afibrinogenemic patient's hepatocytes.

Journal of thrombosis and haemostasis : JTH·2014

Area of Science:

  • Pharmacology
  • Genetics
  • Hematology

Background:

  • Oral anticoagulants, such as coumarins, are crucial for preventing thromboembolic events.
  • Managing anticoagulant therapy requires careful consideration of potential drug-drug interactions and individual patient factors.
  • Bleeding complications can arise from various factors, necessitating thorough investigation.

Observation:

  • Two patients experienced severe bleeding complications while on oral anticoagulant therapy.
  • One case involved pharmacokinetic drug interference from phenylbutazone.
  • Another case was attributed to a genetic predisposition to bleeding induced by coumarin anticoagulants.
  • A third patient showed a decreased International Normalized Ratio (INR) due to drug interference from rifampicin.

Findings:

  • Drug interactions significantly impact the efficacy and safety of oral anticoagulant treatment.
  • Genetic factors, specifically a founder mutation in the factor IX propeptide, can predispose patients to bleeding.
  • Changes in medication regimens for patients on oral anticoagulants necessitate anticipation of potential drug interferences.
  • Identifying genetic predispositions is crucial for patients experiencing hemorrhagic complications despite therapeutic INR levels.

Implications:

  • Clinicians must proactively assess medication changes in patients undergoing oral anticoagulant therapy to prevent adverse events.
  • Screening for genetic predispositions to bleeding should be considered in patients with unexplained hemorrhagic complications.
  • This highlights the importance of personalized medicine in anticoagulant management.
  • Enhanced monitoring and risk stratification can improve patient outcomes and reduce healthcare burdens.

Related Experiment Videos